Synonyms: SHR-3824 | SHR3824
henagliflozin is an approved drug
Compound class:
Synthetic organic
Comment: Henagliflozin (SHR-3824) is an orally active inhibitor of the the renal sodium glucose co-transporter 2 (SGLT2). It was designed to treat type 2 diabetes mellitus (T2DM).
|
|
No information available. |
Summary of Clinical Use ![]() |
Phase 3 trial results were published in 2021 [1]. The Chinese drug regulator (NMPA) approved henagliflozin (Ruiqin®) in June 2024, to treat type 2 diabetes mellitus, typically as add-on therapy to metformin. |